Letters, Testimony & Comments
Jeffrey S. Hatfield, President and Chief Executive Officer, Vitae Pharmaceuticals
On behalf of the Biotechnology Industry...
July 26 2012
Dear Majority Leader Reid and Minority Leader McConnell:
On behalf of the Biotechnology Industry Organization (BIO) and its more than 1...
March 16 2012
William D. Waddill, Senior Vice President and Chief Financial Officer OncoMed Pharmaceuticals highlights the importance of capital...
March 6 2012
December 1, 2011
On December 1, BIO submitted written testimony to the Senate Committee on Banking, Housing, and Urban Affairs on the importance of...
December 1 2011
May 25, 2011
Good morning Chairman Casey, Vice Chairman Brady, Ranking Member DeMint, Ranking Member Hinchey, Members of the Committee, ladies, and...
May 25 2011
May 17, 2011
Dear Chairman Frelinghuysen and Ranking Member Visclosky:
On behalf of the Biotechnology Industry Organization (BIO), I am writing to...
May 17 2011
April 7, 2011
Hearing Testimony
Scott Koenig, M.D., PH.D.
Before the House of Representatives Committee on Small Business
Good morning Chairman...
April 7 2011
April 1, 2011
Re: Request for Comments on the Strategy for American Innovation
Subject: Innovation Strategy RFI
Email: competitiveness@doc.gov
Dear...
April 1 2011
SECTION 1. PURPOSE
This notice establishes the qualifying therapeutic discovery project program under § 48D of the Internal...
August 3 2010
August 3, 2010
BIO advocated for the recently enacted new Therapeutic Discovery Project Credit program, which was created as a unique opportunity for...
August 3 2010
June 23, 2010
A letter to the House Ways & Means Committee by 54 trade organizations and companies supporting the extension of cellulosic biofuel...
June 23 2010
June 1, 2010
Dear Chairman Inouye and Ranking Member Cochran:
As the Senate debates fiscal year 2011 federal funding, the undersigned organizations...
June 1 2010
May 27, 2010
Access to Early Capital
In the United States and globally, commercial development of biotechnology relies on the continuing...
May 27 2010
May 17, 2010
BIO and 34 companies and trade organizations sent a letter to Chairman Levin and Ranking Member Camp, of the House Ways and Means...
May 17 2010
November 3, 2009
Dear Ms. Blue,
This letter is submitted by the Biotechnology Industry Organization (BIO) in response to the request for public comment...
November 3 2009
October 14, 2009
Good morning Chairwoman Velázquez, Ranking Member Graves, Members of the Committee, the Staff of the Committee, ladies and...
October 14 2009
April 23, 2009
Good morning Chairman Wu, Ranking Member Smith, Members of the Committee, ladies and gentleman. I am Jim Greenwood, President and CEO of...
April 23 2009
April 20, 2009
Re: Release No. 33-8982; File No. S7-27-08; Roadmap for the Potential Use of Financial Statements Prepared in Accordance with...
April 20 2009
November 15, 2008
BIO urges that changes to FIN46(R) accurately reflect the underlying economics of collaborations.
November 15 2008
October 27, 2008
Re: SEC Release No. 34-58572
Dear Chairman Cox:
On behalf of its members, the Biotechnology Industry Organization (“BIO...
October 27 2008
September 22, 2008
Dear Chairman Cox and Director Thomsen:
On behalf of its members, the Biotechnology Industry Organization (“BIO”) would...
September 22 2008
September 18, 2008
The letter, signed by approximately 60 patient groups, emphasizes support for restoring eligibility in the SBIR program to venture-backed...
September 18 2008
October 27, 2007
BIO addresses concerns to FASB’s Staff Position on accounting for instrument C and conventional convertible debt.
October 27 2007
August 27, 2007
The Biotechnology Industry Organization (BIO) appreciates this opportunity tp provide the perspective of its members on the Bayh-Dole Act...
August 27 2007
July 26, 2005
The letter, signed by over 280 biotech executives, emphasizes support for restoring eligibility in the SBIR program to venture-backed...
July 26 2005
March 25, 2004
March 25 2004
December 10, 2003
December 10 2003
November 4, 2003
To Hector Barreto, Administrator, U.S. Small Business Administration
November 4 2003
October 21, 2003
To Hector Barreto, Administrator, U.S. Small Business Administration
October 21 2003
July 7, 2003
July 7 2003
BIO advocated for a provision in financial services reform that would ease regulatory burdens for small public biotechnology companies....
The 2009 Government-Business Forum on Small Business Capital Formation recommended a permanent exemption for small companies from Section...
Re: Release No. 33-8982; File No. S7-27-08; Roadmap for the Potential Use of Financial Statements Prepared in Accordance with...
Letters, Testimony & Comments
July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer, Vitae Pharmaceuticals
On behalf of the Biotechnology Industry...
March 16 2012
Dear Majority Leader Reid and Minority Leader McConnell:
On behalf of the Biotechnology Industry Organization (BIO) and its more than 1...
March 6 2012
William D. Waddill, Senior Vice President and Chief Financial Officer OncoMed Pharmaceuticals highlights the importance of capital...
December 1 2011
On December 1, BIO submitted written testimony to the Senate Committee on Banking, Housing, and Urban Affairs on the importance of...
May 25 2011
Good morning Chairman Casey, Vice Chairman Brady, Ranking Member DeMint, Ranking Member Hinchey, Members of the Committee, ladies, and...
Press Releases
January 8 2013
WASHINGTON DC, January 8, 2013 -- BIO lauds the Administration and the U.S. Small Business Association (SBA) for...
September 25 2012
Washington, D.C. (September 25, 2012) – The Biotechnology Industry Organization (BIO) applauds Sens. Robert...
July 26 2012
Washington, D.C. (July 26, 2012) – Today, the House Subcommittee on Capital Markets held a hearing entitled...
July 20 2012
Washington, D.C. (July 20, 2012) – Today, Representative Michael Fitzpatrick (R-PA) introduced H.R. 6161, the...
June 6 2012
Washington, DC and New York, NY, Wednesday, June 6, 2012 -The 4th Annual Scientific American Worldview Report and...
Receive our newsletter from BIOtechNOW
Business Solutions Sponsor
